Adamax
Cognitive & NootropicResearch-GradeNo Peer-Reviewed EvidenceLast reviewed: July 20, 2026
Quick Facts
- What it is
- A vendor-marketed, doubly-modified analog of Semax (N-acetyl-Semax with an adamantane group), sold for cognition — but with essentially no peer-reviewed literature of its own. Nearly everything known comes from its parent peptide, Semax.
- How it's taken
- Marketed for intranasal use (primary) or subcutaneous injection — no route validated in any study
- Half-life
- Uncharacterized for Adamax; parent Semax is short (minutes)
- Typical research dose
- No established dose — vendors suggest low-hundreds-of-mcg intranasally by analogy to Semax
- Research status
- Not FDA-approved — research use only. No peer-reviewed literature on Adamax.
On this page
- 1.What is Adamax?
- 2.How does Adamax work?
- 3.What is Adamax used for?
- 4.How long does Adamax take to work?
- 5.How is Adamax dosed?
- 6.How is Adamax administered?
- 7.What does Adamax stack well with?
- 8.What are the side effects of Adamax?
- 9.Does Adamax interact with other drugs?
- 10.How should Adamax be stored?
- 11.What are the limitations of Adamax research?
- 12.Where to source Adamax
- 13.Adamax FAQ
- 14.References
- 15.Published Studies
What is Adamax?
Adamax is a research compound sold by specialty peptide vendors and discussed in nootropic communities as a modified analog of Semax. Vendors describe it as N-acetyl-Semax bearing a C-terminal adamantane group — sold under vendor names such as N-Acetyl Semax Adamantane or NA-Semax-Adamantane, with no official INN or code designation — two chemical modifications intended to make it more lipophilic, more resistant to enzymatic breakdown, and longer-acting than Semax. That description is consistent across vendor sources but has not been confirmed in any peer-reviewed publication. Critically, there is no published scientific literature on Adamax itself: a PubMed search returns no studies on the compound, and every claim about its effects, potency, or pharmacokinetics traces to vendor marketing or anecdotal user reports rather than controlled research. What follows describes what Adamax is marketed as, places it in the context of its real, well-studied parent Semax (clearly labeled as Semax data), and is explicit about where evidence simply does not exist. New to peptide research? Start with the basics →
Reported benefits:
The following are marketed or anecdotally reported — none has been demonstrated in a study of Adamax.
- Claimed sharper focus, executive function, and reduced “brain fog” (user-reported, uncontrolled)
- Claimed longer duration of action than Semax (vendor claim, never measured)
- Proposed BDNF / neuroplasticity support by analogy to Semax (not tested for Adamax)
- Claimed resistance to enzymatic degradation from the adamantane modification (medicinal-chemistry rationale, unverified for this compound)
- Marketed for cognition, stress resilience, and neuroprotection (extrapolated from Semax; no Adamax data)
Common research dose: No established or study-derived dose exists for Adamax. Vendors typically suggest intranasal use in the low-hundreds-of-micrograms range by analogy to Semax — these are vendor suggestions only, not derived from any Adamax pharmacokinetic or dosing study.
Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes → for current options.
How does Adamax work?
Adamax's mechanism has not been studied. Everything vendors describe is inferred from its marketed parent, Semax — a genuinely researched ACTH(4-7) analog. The mechanisms below are Semax mechanisms, offered as family context; whether the adamantane-modified molecule sold as Adamax actually shares any of them is untested.
- No direct evidence. There are no published mechanistic studies on Adamax. The items below describe the parent peptide, Semax, and are presented as analog context — not as evidence for Adamax.
- BDNF / neurotrophin signaling (Semax, parent). Semax — not Adamax — increases BDNF expression across several regions of the rat brain in vivo [2]. Vendors extrapolate a similar, often 'amplified', BDNF effect for Adamax, but this has never been measured for the compound.
- Melanocortin / ACTH-fragment activity (Semax lineage). Semax is derived from the ACTH(4-7)/ACTH(4-10) sequence [1] and is proposed to act partly through melanocortin (e.g. MC4R) signaling. Adamax is marketed as retaining this activity; no data confirm it.
- Enkephalinase inhibition (Semax family). Semax, with the related peptide Selank, inhibits enkephalin-degrading enzymes in human serum [3], which may prolong endogenous opioid signaling. This is a Semax/Selank finding, not an Adamax finding.
- Adamantane modification (theory only). Attaching an adamantane group is a recognized medicinal-chemistry tactic for increasing lipophilicity and metabolic stability. For Adamax this is a plausible rationale for a longer-acting molecule — but it remains theory, with no pharmacokinetic study on the actual compound.
What is Adamax used for?
There is no research on Adamax to summarize. A literature search returns no peer-reviewed preclinical or clinical studies on the compound. The only relevant published evidence concerns its parent, Semax, and is presented here strictly as family context — it is not evidence that Adamax produces the same effects.
- No Adamax studies exist. There are no trials, no animal studies, and no pharmacology or toxicology on Adamax specifically. It is marketed for cognition, focus, stress resilience, and neuroprotection, but none of these applications has been tested for the compound.
- Semax cognition research (parent). Semax has decades of Russian research as a nootropic — improving memory and attention — and a clinical history in Russia [1]. This is Semax, not Adamax.
- Semax and BDNF (parent). Intranasal Semax raises BDNF in the rat brain [2]. Adamax is marketed on the premise of an even stronger BDNF effect; that premise is untested.
- Semax in ischemic stroke (parent, clinical). Semax has been studied in patients during acute ischemic stroke in Russia [4]. No comparable study exists for Adamax.
- Bottom line. Any 'research applications' attributed to Adamax are borrowed from Semax. Treat them as hypotheses about Adamax, not as findings.
How long does Adamax take to work?
Onset and duration for Adamax are not characterized in any study. The figures vendors and users cite are claims, not pharmacokinetic measurements.
Vendors and user reports commonly claim a 20–40 minute onset after intranasal use and a duration longer than Semax (sometimes stated as several hours), attributing the longer action to the adamantane modification. These are marketing and anecdotal claims — no half-life, onset, or duration study has been performed on Adamax. For reference, the parent Semax has a short plasma half-life (on the order of minutes), with biological effects that outlast plasma levels via gene-expression changes; whether Adamax actually extends this is unknown.
How is Adamax dosed?
There is no established dose for Adamax. No pharmacokinetic or dose-ranging study has been conducted, so any numbers below are vendor suggestions or analogies to Semax — not study-derived recommendations.
- No validated dose. No Adamax study has established a safe or effective dose, route, or frequency.
- Vendor-suggested (intranasal). Vendors commonly suggest low-hundreds-of-micrograms intranasally, once or twice daily — presented explicitly as a vendor suggestion by analogy to Semax, not as an evidence-based dose.
- Analogy to Semax has limits. Even a dose borrowed from Semax may not translate: the adamantane modification is claimed to change potency and duration.
- No titration or PK basis. Without pharmacokinetic data, titration, timing, and cycling for Adamax are guesswork.
If you are reconstituting a vial, the arithmetic (mg per vial and bacteriostatic-water volume to syringe units) is the same as any peptide — use the dosage calculator →. Because no dose is established for Adamax, treat any resulting number as arbitrary until real dosing data exists.
How is Adamax administered?
Adamax is marketed primarily for intranasal use (like Semax), with subcutaneous use also mentioned. The practical notes below are general peptide-handling conventions — there is no Adamax-specific administration protocol validated in any study. For subcutaneous technique, see the syringes and injection technique guide.
- Route. Marketed intranasal (primary) or subcutaneous. No route has been validated for Adamax.
- Time of day. Not established. Earlier in the day is suggested by analogy to Semax's mild stimulating effect, but this is extrapolation.
- Concentration. There is no established Adamax concentration or vial convention. Any recon volume is arbitrary in the absence of an established dose.
- Missed dose / cycle. Not defined — no protocol exists to be consistent with.
- Identity caveat. Because commercial Adamax is uncharacterized in the literature, technique cannot compensate for not knowing exactly what the material is — vendor third-party testing matters.
Timing context. None of the timing variables that matter for a peptide — onset, duration, frequency, cumulative effect — has been measured for Adamax. The table below is therefore mostly a record of what is not known, with the parent Semax noted where relevant.
| Aspect | What is known |
|---|---|
| Frequency | Not established — vendor suggestions only (commonly 1–2×/day) |
| Best time of day | Not established; earlier in the day suggested by analogy to Semax |
| Food | No data; peptides of this class are generally food-independent |
| Route | Marketed intranasal or subcutaneous; no route validated for Adamax |
| Half-life | Uncharacterized for Adamax. Parent Semax: short (minutes). Claimed longer duration is unmeasured. |
| Steady-state | Unknown — no pharmacokinetic data exist |
Reconstitution. There is no established Adamax vial size, concentration, or dose, so a fixed reconstitution table would imply a precision that does not exist. The arithmetic is standard for any peptide — divide vial mass by bacteriostatic-water volume for concentration, then convert your chosen dose to U-100 syringe units with the dosage calculator. Any dose entered is a guess until dosing data exists.
What does Adamax stack well with?
There are no studied Adamax stacks. In nootropic communities it is combined with other cognitive compounds, but no combination has been tested for Adamax specifically. The pairings below are anecdotal and unverified.
- Standalone. The most common way it is used — and still entirely unstudied.
- Semax / Selank (family). Some users run Adamax alongside or in place of Semax or Selank. As the marketed parent, Semax is the one with an actual evidence base; no study has compared or combined Adamax with either.
- Racetams / choline sources. A common anecdotal nootropic pairing. No interaction or efficacy data for Adamax.
- Caffeine / L-theanine. Reported anecdotally; no data on any interaction with Adamax.
What are the side effects of Adamax?
Adamax has no published safety data of any kind — no toxicology and no adverse-event reporting from any trial, because there are no trials. What appears below is limited to scattered anecdotal reports and to the generally mild profile of its parent, Semax, in Semax studies. Absence of reported harm here reflects absence of study, not demonstrated safety.
Common (anecdotal, unverified)
- Mild nasal irritation. Reported with intranasal use; user-reported, not from any study.
- Mild headache. Occasionally reported; inconsistent across users.
- Overstimulation / disrupted sleep if dosed late. Reported by analogy to Semax's mild stimulating effect.
Uncertain (no data)
- Systemic effects. Uncharacterized. No study has looked for them.
- Individual variability. Unknown — there is no cohort data of any size.
Serious (unknown — no data)
- No toxicology or long-term safety data exist for Adamax. Serious risks can be neither confirmed nor ruled out.
- Unverified identity and purity. Because commercial Adamax has no published characterization, what is in a given vial is itself a safety consideration.
The honest summary is that Adamax's safety is simply unknown. Its parent Semax has a clean profile in Semax studies, but a modified molecule can behave differently, and none of that work was done on Adamax.
Does Adamax interact with other drugs?
No drug interactions have been studied for Adamax. The notes below are theoretical, by analogy to the parent Semax, and should not be read as established.
- No interaction data. No drug-drug interaction has been characterized for Adamax in any study.
- Theoretical, by analogy to Semax (parent). If Adamax shares Semax's neurotrophic and neurotransmitter-modulating activity, ordinary caution with serotonergic or other CNS-active drugs would be prudent — but this is extrapolation, not evidence.
- Unknown for everything else. With no pharmacokinetic or metabolism data, interactions with other medications cannot be predicted.
How should Adamax be stored?
- Lyophilized (powder) form: store at -20°C for long-term storage; refrigerate at 2–8°C for short-term.
- Reconstituted solution: store at 2–8°C; do not freeze; use within a few weeks.
- Reconstitute with bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
- Protect from light. Store in the original carton or an amber dropper bottle.
- Discard if the solution is cloudy, discolored, or contains particles.
- Storage cannot compensate for identity: because commercial Adamax is uncharacterized in the literature, correct handling still does not guarantee a defined product.
What are the limitations of Adamax research?
This is the most important section on the page. Adamax is a compound with essentially no scientific record — the limitations are not caveats around a body of evidence, they are the evidence situation.
No peer-reviewed literature. A PubMed search returns no studies on Adamax. There is no preclinical or clinical evidence for its effects, potency, pharmacokinetics, or safety.
Claims are marketing or anecdotal. Every stated benefit, onset, duration, and dose traces to vendor pages or user reports, not to controlled research.
Structure and identity unconfirmed. The “N-acetyl-Semax plus adamantane” description is a vendor description. No independent published work confirms the structure of the material sold as Adamax, and purity and identity vary by vendor.
Semax evidence does not transfer. Semax is genuinely studied — but chemical modifications can change activity, potency, duration, and safety. Semax data is context, not a substitute for Adamax data.
Not approved anywhere; research-use-only. Adamax has no regulatory status with any agency and is not intended for human consumption.
Where to source Adamax
Adamax is a niche compound sold by a small number of specialty research-peptide vendors as research-use-only material. Given the complete absence of published characterization, third-party testing (HPLC purity and mass-spectrometric identity) matters even more than usual — you are relying entirely on the vendor's documentation to know what the material is.
Prefer vendors that publish batch-specific Certificates of Analysis with both purity and identity data. Because there is no reference literature for Adamax, an identity confirmation (mass spectrometry) is the only way a vendor can substantiate what the compound actually is.
Adamax FAQ
Is there any published research on Adamax?
No. A PubMed search returns no studies on Adamax — no clinical trials, no animal studies, no pharmacology, and no toxicology on the compound. Everything published about it is vendor marketing or anecdotal user reports. The only genuine peer-reviewed literature in this space is on its marketed parent peptide, Semax.
What is Adamax, exactly?
It is marketed as a doubly-modified analog of Semax — N-acetyl-Semax carrying a C-terminal adamantane group — intended to be more lipophilic, more resistant to enzymatic breakdown, and longer-acting than Semax. That structure is a vendor description; no independent peer-reviewed publication has confirmed the structure or identity of the material sold as Adamax.
Is Adamax the same thing as Semax?
No. Semax is a genuinely researched ACTH(4-7) analog with decades of Russian studies behind it. Adamax is marketed as a further-modified derivative of Semax that has no studies of its own. They are related, but Semax's evidence does not automatically transfer to Adamax — chemical modifications can change activity, potency, duration, and safety.
Is Adamax safe?
Unknown. There is no toxicology or safety data on Adamax of any kind. Its parent Semax is generally well tolerated in Semax studies, but that does not establish Adamax's safety — and because commercial Adamax has no published identity or purity characterization, you are also relying entirely on a vendor's documentation to know what the material actually is.
What is a typical Adamax dose?
There is no established dose. No pharmacokinetic or dose-ranging study exists for Adamax, so any figure is a vendor suggestion or an analogy to Semax rather than an evidence-based recommendation. Because the adamantane modification is claimed to change potency and duration, even a Semax-derived dose may not translate.
Where can I buy Adamax?
Adamax is sold by a small number of specialty research-peptide vendors as research-grade material. Given the absence of any published characterization, third-party testing (HPLC purity and mass-spectrometric identity) matters more than usual. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes →.
References
There are no references for Adamax itself — no peer-reviewed study has been published on the compound. The references below are studies of the parent peptide Semax (and the related peptide Selank), included only as family context. None is evidence for Adamax.
- Semax (parent), not Adamax. Asmarin IP, Nezavibat'ko VN, Miasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-Semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997. https://pubmed.ncbi.nlm.nih.gov/9173745/
- Semax (parent), not Adamax. Dolotov OV, Seredenina TS, Levitskaya NG, et al. The heptapeptide Semax stimulates BDNF expression in different areas of the rat brain in vivo. Dokl Biol Sci. 2003. https://pubmed.ncbi.nlm.nih.gov/14556513/
- Semax / Selank (family), not Adamax. Kost NV, Sokolov OY, Gabaeva MV, et al. Semax and Selank inhibit the enkephalin-degrading enzymes from human serum. Russ J Bioorg Chem. 2001. https://pubmed.ncbi.nlm.nih.gov/11443939/
- Semax (parent), clinical, not Adamax. Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of Semax in the acute period of hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1997. https://pubmed.ncbi.nlm.nih.gov/11517472/
Published Studies
There are no published studies on Adamax. The summaries below are of its parent peptide Semax (and, in one case, the related peptide Selank), included only to show what the family has — and has not — demonstrated. None is evidence for Adamax.
Asmarin IP, Nezavibat'ko VN, Miasoedov NF, et al.
SEMAX STUDY — family context, not Adamax. A review of the design and study of Semax, the ACTH(4-10)/ACTH(4-7)-derived heptapeptide from which Adamax is marketed as being modified. It documents Semax's nootropic profile — stimulation of operative memory and attention, increased resistance to hypoxia, and improved brain circulation. This is the real, researched parent compound; it is included to show what family Adamax is claimed to belong to, and is not evidence that Adamax shares these properties.
Dolotov OV, Seredenina TS, Levitskaya NG, et al.
SEMAX STUDY — family context, not Adamax. Intranasal Semax increased brain-derived neurotrophic factor (BDNF) expression across several regions of the rat brain in vivo. Vendors extrapolate an even stronger BDNF effect for Adamax on the strength of its adamantane modification, but no such measurement has ever been made on Adamax — this finding is about Semax only.
Kost NV, Sokolov OY, Gabaeva MV, et al.
SEMAX / SELANK STUDY — family context, not Adamax. Semax and the related peptide Selank inhibited enkephalin-degrading enzymes in human serum, a mechanism that may prolong endogenous opioid signaling and contribute to anti-stress effects. This is a parent/family finding; whether the modified molecule sold as Adamax retains this activity is untested.
Gusev EI, Skvortsova VI, Miasoedov NF, et al.
SEMAX STUDY — family context, not Adamax. A clinical study of Semax in 30 patients during the acute period of hemispheric ischemic stroke (vs 80 controls on standard therapy), using clinical scales and EEG/evoked-potential mapping. Semax — not Adamax — has this clinical history in Russia. No comparable study of any kind exists for Adamax.
Related Blends
Need to calculate a dose?
Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.
Open CalculatorWe may earn commissions from peptide vendor affiliate links.
Have a question about Adamax? Send us an email →
